Skip to content
Biodatica
Start free

R-Pharm

Kursk, Kursk Oblast

OncologyPhase III
Compare Sign in to watch

What changed

Phase I trial registered: Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

5d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Apr 17, 2025

    Metastatic Colorectal Cancer · RECRUITING · sponsor: R-Pharm · A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

    ClinicalTrials.gov · NCT07543744 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Aug 9, 2024

    Locally Advanced Breast Cancer, Metastatic Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: R-Pharm · A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

    ClinicalTrials.gov · NCT07386938 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Aug 8, 2024

    Head and Neck Squamous Cell Carcinoma · COMPLETED · sponsor: R-Pharm · A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

    ClinicalTrials.gov · NCT07435324 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Sep 27, 2023

    Skin Melanoma · COMPLETED · sponsor: R-Pharm · Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

    ClinicalTrials.gov · NCT06320353 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Mar 1, 2023

    Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma · COMPLETED · sponsor: R-Pharm · Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

    ClinicalTrials.gov · NCT06307093 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Jun 15, 2020

    Head and Neck Squamous Cell Carcinoma · COMPLETED · sponsor: R-Pharm · A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

    ClinicalTrials.gov · NCT07435311 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources